Skip to Content


Active Substance: lepirudin
Common Name: lepirudin
ATC Code: B01AE02
Marketing Authorisation Holder: Celgene Europe Ltd.
Active Substance: lepirudin
Status: Withdrawn
Authorisation Date: 1997-03-13
Therapeutic Area: Thromboembolism Thrombocytopenia
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Anticoagulation in adult patients with heparin-induced thrombocytopenia type II and thromboembolic disease mandating parenteral antithrombotic therapy.

The diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

The marketing authorisation for Refludan has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.